Caedo Oncology AS

Caedo Oncology AS is a biotechnology company dedicated to creating improved treatment options for cancer patients through unique immunotherapy opportunities. With a vision to be a leader in cancer immunotherapy, Caedo Oncology focuses on improving patient treatment through novel monoclonal antibodies, inducing programmed cell death in cancer cells. Caedo Oncology is committed to advancing cancer treatment by selectively targeting cancer cells, shifting away from traditional cytotoxic approaches that affect both cancer and healthy cells.

Caedo Oncology develops new strategies for monoclonal antibody-based therapy centered around the activation of distinctive pathways for cell death in cancer cells. Established in November 2020, Caedo Oncology builds upon research performed at Oslo University Hospital. The primary address of Caedo Oncology is Forskningsparken, Gaustadalléen 21, Oslo, 0349, NO.

Caedo Oncology aims to make significant contributions to the field of cancer immunotherapy. The team at Caedo Oncology is focused on developing innovative solutions that will improve the lives of cancer patients worldwide. We invite the management team at Caedo Oncology AS to create a customized and exclusive company showcase and product listing on our platform to further enhance your commercial development.